First clinical evidence published on AROA’s ENIVO system for surgical dead space management
August 28, 2025
AROA is pleased to announce the findings of the first in human study involving its…
Read MoreSeptember 2024– Quarterly Results
October 22, 2024
Aroa Biosurgery Limited (ASX: ARX, ‘AROA’ or the ‘Company’) is pleased to provide an update…
Read MoreFull Year FY24 Results
May 21, 2024
Aroa Biosurgery is pleased to provide audited full year financial results for FY24. Highlights are…
Read MoreMarch 2024– Quarterly Results
April 30, 2024
Aroa Biosurgery Limited (ASX: ARX, ‘AROA’ or the ‘Company’) is pleased to provide an update…
Read MoreAROA named Supreme Business Excellence winner at 2Degrees Auckland Business Awards
April 19, 2024
AROA has been recognised for its commitment to innovation and business excellence, taking out both…
Read MoreSeasoned global commercial operations executive Darla Hutton joins AROA’s Board, and Steven Engle to retire.
March 21, 2024
Aroa Biosurgery Limited is pleased to announce the appointment of Darla Hutton as an independent…
Read MoreDecember 2023 – Quarterly Results
January 30, 2024
Aroa Biosurgery Limited (ASX: ARX) is pleased to announce financial results for the December 2023…
Read MoreClinical evidence from Enivo™ Pilot Study paves the way for potentially new therapy
January 25, 2024
Highlights • AROA’s Enivo™ system is showing promise in the management of ‘dead space’ after mastectomy….
Read MoreH1 FY24 – Results Announcement
November 29, 2023
Aroa Biosurgery Limited (ASX: ARX) is pleased to announce its results for the first half…
Read MoreSeptember 2023 – Quarterly Results
October 31, 2023
Aroa Biosurgery Limited (ASX: ARX) is pleased to announce financial results for the September 2023…
Read MoreNew Study highlights positive outcomes using Myriad Matrix™ and Myriad Morcells™ in complex traumatic wounds.
October 4, 2023
Highlights Clinical outcomes from the use of AROA’s Myriad Matrix™ and Myriad Morcells™ products have…
Read MoreSoft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX) is pleased to announce financial results for the March 2023 Quarter.
July 31, 2023
Highlights are listed below. To read the full announcement, click here Financial Highlights Increased cash…
Read MoreFY23 Annual Report available now
July 19, 2023
AROA is pleased to advise it’s FY23 Annual Report is available now. To find out…
Read MoreScott Sherriff appointed as inaugural Chief Operating Officer
June 15, 2023
Aroa Biosurgery (AROA, ASX: ARX) is delighted to announce the appointment of seasoned executive Scott…
Read MoreFY23 Full Year Results and Outlook for FY24
May 31, 2023
AROA is pleased to release its audited full year results for the period ended 31…
Read MoreMarch 2023 – Quarterly Results
April 27, 2023
Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX) is pleased to announce financial results…
Read MoreAROA SECURES FIRST FDA CLEARANCE FOR ENIVO™ SYSTEM.
April 12, 2023
Highlights • AROA has received U.S. FDA 510K clearance for its Enivo™ pump and catheter,•…
Read MoreDr Brian Ward inducted into Biotech New Zealand Hall of fame.
March 31, 2023
The inaugural Biotech NZ Life Sciences Summit was held in Wellington on March 22 and…
Read MoreAROA AWARDED REGENERATIVE SKIN GRAFTING PRODUCTS AGREEMENT WITH PREMIER, INC.
March 14, 2023
Highlights AROA has been awarded a group purchasing agreement for its Myriad™ and Symphony™ products,…
Read MoreNPWT and Collagen matrices study
February 20, 2023
First of its kind study shows promising results for combined use of negative pressure wound…
Read MoreDecember 2022 Quarterly Results
January 31, 2023
Aroa Biosurgery Limited (ASX: ARX, ‘AROA’ or the ‘Company’) is pleased to provide an update…
Read MoreAroa Biosurgery Half Yearly Report H1 FY23
November 29, 2022
Today Aroa Biosurgery (AROA, the Company) is pleased to announce financial results for H1 FY23….
Read MoreDr Catherine Mohr to join AROA Board of directors
September 13, 2022
Aroa Biosurgery, (AROA) is delighted to announce the appointment of award-winning medical researcher and inventor,…
Read More2022 AGM Update
August 9, 2022
Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, ‘AROA’ or the ‘Company’)advises that following recent…
Read MoreAroa Biosurgery Half Yearly Report H1 FY23
November 25, 2021
Today Aroa Biosurgery (AROA, the Company) is pleased to announce financial results for H1 FY23….
Read MoreReal-World Data shows Aroa Biosurgery’s Endoform™ Natural achieves significantly improved wound closure for Diabetic Foot Ulcers compared to traditional collagen dressings
August 10, 2021
Highlights A retrospective analysis of real-world data published in the ‘International Wound Journal’ compared the…
Read MoreAroa Biosurgery’s Myriad Matrix receives validation for reconstruction of tissues affected by Pilonidal Sinus Disease
August 4, 2021
Highlights• AROA’s Myriad Matrix™ is further validated in a clinical study and peer-reviewed publication in…
Read MoreAroa Biosurgery June 2021 4C – Commentary
July 16, 2021
HIGHLIGHTS US medical procedure numbers continue to reflect a positive trend supporting improved sales momentum….
Read MoreAroa Biosurgery releases FY2021 Annual Report
June 21, 2021
Aroa Biosurgery is pleased to release its first Annual Report since successfully completing its IPO…
Read MoreAroa Biosurgery March 2021 4C – Commentary
April 28, 2021
HIGHLIGHTS H2 FY21 product revenues (unaudited) grew 16% on H2FY20 to $13.8m on a constant…
Read MoreAroa Biosurgery secures FDA clearance for new product, Myriad Morcells™, offering highly conformable tissue regeneration in wound beds
April 6, 2021
HIGHLIGHTS U.S. FDA 510(k) clearance received for a new Aroa Biosurgery product named Myriad Morcells™,…
Read MorePilot study indicated benefits of Aroa Biosurgery’s Myriad™ in surgical reconstruction of chronic wounds
February 16, 2021
HIGHLIGHTS Aroa’s Myriad™ may be used successfully under a tissue flap to reduce surgical complications…
Read MoreAroa Biosurgery to further expand fully dedicated sales team for key U.S. market
February 2, 2021
HIGHLIGHTS Aroa to expand on its own direct field sales presence in the United States…
Read MoreNew study shows Aroa Biosurgery’s Myriad™ efficacy in healing exposed vital body structures
December 16, 2020
HIGHLIGHTS Aroa’s Myriad™ is further validated in a clinical study and peer-reviewed publication – Journal…
Read MoreIndian regulatory approval received for three Aroa products
December 9, 2020
HIGHLIGHTS The national regulatory authority of India, the Central Drugs Standard Control Organisation (CDSCO), approves…
Read MoreAroa Biosurgery’s Myriad™ shown to be effective in surgical treatment of Hidradenitis Suppurativa
November 12, 2020
HIGHLIGHTS Further validation for Aroa’s MyriadTM from clinical study and peer-reviewed publication in Journal of…
Read MoreAroa Biosurgery’s Endoform® platform shown to attract stem cells
August 19, 2020
HIGHLIGHTS Further validation gained for Aroa’s proprietary Endoform® platform with peer-reviewed publication in PLOS ONE….
Read MoreEuropean approval received for Myriad™
July 30, 2020
HIGHLIGHTS CE Mark to allow commercialization of Aroa’s Myriad™ product in the EU Myriad™ is…
Read MoreAroa Biosurgery secures FDA Clearance for Symphony™
July 30, 2020
HIGHLIGHTS U.S. FDA clearance received for a new Aroa Biosurgery product Symphony™, designed to support…
Read MoreAroa Biosurgery to list on the ASX in $225m IPO
June 23, 2020
Auckland-based soft tissue regeneration company Aroa Biosurgery Limited (Aroa) is set to list on the…
Read MoreAroa Biosurgery opens new pathway for advanced wound treatment amidst COVID-19 disruption in the United States
March 31, 2020
San Diego, U.S. Soft tissue repair company Aroa Biosurgery is stepping up to support clinicians…
Read MoreCOVID-19 Update – Aroa Biosurgery is well placed to maintain supply of Endoform® and Myriad™ products to clinicians and patients
March 25, 2020
Aroa Biosurgery is taking the appropriate precautions and measures amid a rapidly changing global picture…
Read MoreAroa Biosurgery expands options for soft tissue repair with launch of Myriad™
February 21, 2020
Auckland, NZ. Aroa Biosurgery, the Auckland-based privately held soft-tissue repair company, has launched Myriad™, a…
Read MoreAroa Biosurgery launches large format Endoform® to treat larger, more complex wounds
February 16, 2020
Auckland, NZ. Aroa Biosurgery, the Auckland-based privately held soft-tissue repair company, has now launched a…
Read MoreAroa Biosurgery appoints experienced Australian-based director
December 13, 2019
Auckland, NZ. Aroa Biosurgery Limited (Aroa), a New Zealand-headquartered, privately held soft-tissue repair company has…
Read MoreAroa Biosurgery appoints new Vice President, Commercial
October 17, 2019
Auckland, NZ. Aroa Biosurgery a New Zealand-headquartered, emerging global leader for tissue regeneration products used…
Read MoreAroa Biosurgery grows into additional markets with positive outcomes from Canadian clinical study
October 3, 2019
Auckland, NZ. Aroa Biosurgery, the Auckland-based privately held tissue-regeneration company, has this week presented positive…
Read MoreAroa Biosurgery posts maiden profit as it expands sales presence in U.S. and global markets
September 12, 2019
Auckland, NZ. Aroa Biosurgery has posted a modest profit for the FY18/19 year, a first…
Read MoreTELA Bio begins commercialization for Large Size OviTex® Reinforced BioScaffolds for Hernia Repair and Abdominal Wall Reconstruction after Aroa Biosurgery receives 510k clearance.
January 21, 2019
1,000 cm2 device now commercially available in the U.S. rounds out portfolio of surgical mesh…
Read MoreTELA Bio® Announces Initial Data from BRAVO Study of OviTex® Reinforced BioScaffolds for Ventral Hernia Repair
June 26, 2018
Early outcomes from post-market clinical study presented at Abdominal Wall Reconstruction Conference in Washington, DC….
Read MoreTELA Bio® Announces Plans to Launch OviTex® Reinforced BioScaffolds in Europe
June 11, 2018
MALVERN, Pa., May 31, 2018 /PRNewswire/ — TELA Bio®, Inc., a surgical reconstruction company leading…
Read MoreAroa Biosurgery and Hydrofera Team up in US
June 4, 2018
MANCHESTER, Conn. & AUCKLAND, New Zealand–(BUSINESS WIRE)–New Zealand biomedical company Aroa Biosurgery and United States…
Read MoreFDA Clearance for Endoform® Silver Dermal Template
November 27, 2017
Aroa Biosurgery has been granted U.S. Food and Drug Administration (FDA) 510(k) clearance for the…
Read MoreBig investment in Aroa Biosurgery‘s Commercial Partner
October 31, 2017
New Zealand biomedical company Aroa Biosurgery faces accelerating growth after a significant investment of up…
Read MoreEC Certification for Endoform® Dermal Template
May 17, 2017
Aroa Biosurgery has received EC Certification for its Endoform® Dermal Template (“EDT”), which allows the…
Read More510(k) Clearance Received for Endoform® Plastics and Reconstructive Matrix
March 12, 2017
Aroa Biosurgery has been granted U.S. Food and Drug Administration (FDA) 510(k) clearance for the…
Read MoreAroa Biosurgery successfully raises additional capital to fund growth
March 12, 2017
Aroa Biosurgery has successfully raised additional capital from new and existing investors from the USA,…
Read MoreLaunch of Ovitex Reinforced Bioscaffolds
March 12, 2017
Aroa Biosurgery’s partner, TelaBio, Inc. announced today, the commercial launch of the Ovitex™ Reinforced Bioscaffolds…
Read MoreAroa Biosurgery wins NZBIO top award
October 12, 2015
NZBIO delegates pick Aroa Biosurgery for top honour Aroa Biosurgery has been named as New…
Read MoreAroa Biosurgery poised for global growth
June 19, 2015
Mesynthes renamed for new strategic direction Auckland June 22, 2015: Mesynthes Ltd, a privately held…
Read MoreAroa Corporate Update
February 27, 2015
Aroa has changed a lot over the last seven years. We started as a company…
Read More